No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma
Authors:
- Annette J VangstedAVAnnette J Vangsted
- Karen SøebyKSKaren Søeby
- Tobias W KlausenTKTobias W Klausen
- Niels AbildgaardNANiels Abildgaard
- Niels F AndersenNANiels F Andersen
- Peter GimsingPGPeter Gimsing
- Henrik GregersenHGHenrik Gregersen
- Ulla VogelUVUlla Vogel
- Thomas WergeTWThomas Werge
- Henrik B RasmussenHRHenrik B Rasmussen
Open Access
- 4 August 2010
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 404
Abstract
The response to treatment varies among patients with multiple myeloma and markers for prediction of treatment outcome are highly needed. Bioactivation of cyclophosphamide and thalidomide, and biodegradation of bortezomib, is dependent on cytochrome P450 metabolism. We explored the potential influence of different polymorphisms in the CYP enzymes on the outcome of treatment.Keywords
This publication has 18 references indexed in Scilit:
- Improved survival of multiple myeloma patients with late relapse after high‐dose treatment and stem cell support, a population‐based study of 348 patients in Denmark in 1994–2004*European Journal of Haematology, 2010
- A polymorphism in NFKB1 is associated with improved effect of interferon- maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell supportHaematologica, 2009
- Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scalesPharmacogenetics and Genomics, 2009
- Treatment of newly diagnosed myelomaLeukemia, 2008
- The polymorphism IL-1β T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCTBone Marrow Transplantation, 2008
- Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantationInternational Journal of Cancer, 2006
- RELATIVE CONTRIBUTIONS OF THE FIVE MAJOR HUMAN CYTOCHROMES P450, 1A2, 2C9, 2C19, 2D6, AND 3A4, TO THE HEPATIC METABOLISM OF THE PROTEASOME INHIBITOR BORTEZOMIBDrug Metabolism and Disposition, 2005
- HUMAN METABOLISM OF THE PROTEASOME INHIBITOR BORTEZOMIB: IDENTIFICATION OF CIRCULATING METABOLITESDrug Metabolism and Disposition, 2005
- Clinical application of pharmacogeneticsTrends in Molecular Medicine, 2001
- Ultrarapid metabolizers of debrisoquine: Characterization and PCR‐based detection of alleles with duplication of the CYP2D6 geneFEBS Letters, 1996